NCT07104955 Salutare One Referral Software Impact on Multi-Disciplinary Team (MDT) Meetings Effectiveness and Safety
| NCT ID | NCT07104955 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Salutare Group Ltd. |
| Condition | Cancer (Solid Tumors) |
| Study Type | INTERVENTIONAL |
| Enrollment | 40 participants |
| Start Date | 2025-07-31 |
| Primary Completion | 2026-06-19 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 40 participants in total. It began in 2025-07-31 with a primary completion date of 2026-06-19.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Multi-Disciplinary Team (MDT) meetings are crucial for planning patient care in the National Health Service (NHS), but they can be time-consuming and sometimes lack complete patient information. This can lead to delays in treatment decisions, potentially incomplete care plans, or the need to repeatedly discuss the same patient cases. This study aims to test a new software called Salutare One Referral. One Referral is designed to make these meetings more efficient and effective. We want to see if this software can help healthcare staff prepare MDT referral information more easily and facilitate a more informed MDT discussion, which could lead to better patient care. If successful, this could help improve how MDTs operate across the NHS.
Eligibility Criteria
Inclusion Criteria: * MDT meeting Panel Members, Coordinators and staff submitting MDT referrals will take part in this study. Exclusion Criteria: * MDT meeting Panel Members, Coordinators and staff submitting MDT referrals who are unwilling or unable to take part in the study.
Contact & Investigator
Kevin Moore, MD
PRINCIPAL INVESTIGATOR
Salutare Limited
Frequently Asked Questions
Who can join the NCT07104955 clinical trial?
This trial is open to participants of all sexes, studying Cancer (Solid Tumors). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07104955 currently recruiting?
Yes, NCT07104955 is actively recruiting participants. Contact the research team at liba@dicro.co.uk for enrollment information.
Where is the NCT07104955 trial being conducted?
This trial is being conducted at London, United Kingdom.
Who is sponsoring the NCT07104955 clinical trial?
NCT07104955 is sponsored by Salutare Group Ltd.. The principal investigator is Kevin Moore, MD at Salutare Limited. The trial plans to enroll 40 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.